Fisetin: The Strawberry Flavonoid Reshaping Senescent-Cell Research

Fisetin is a naturally occurring flavonol found most abundantly in strawberries (about 160 µg per gram fresh weight), with smaller amounts in apples, persimmons, kiwis, grapes, cucumbers, and onions. Long classified as a garden-variety antioxidant, fisetin has emerged over the past decade as one of the most promising senolytic compounds yet identified — a class of molecules that selectively eliminate senescent cells, the dysfunctional “zombie cells” that accumulate with age and drive chronic inflammation, tissue decline, and many age-related diseases.

This article reviews what senescent cells are, how fisetin targets them, the landmark Mayo Clinic research that reset attention on this obscure flavonoid, current human-trial status, dosing approaches, and the limits of the evidence.

Table of Contents

  1. What Senescent Cells Are — The Zombie Cell Problem
  2. The Mayo Clinic Fisetin Study
  3. Mechanism — How Fisetin Eliminates Senescent Cells
  4. Beyond Senolytics: Antioxidant, Anti-Inflammatory, Neuroprotective
  5. Current Human Trials
  6. Dosing Approaches
  7. Food Sources
  8. Safety and Limits of the Evidence
  9. Research Papers
  10. Connections
  11. Featured Videos

What Senescent Cells Are — The Zombie Cell Problem

When cells are damaged beyond repair — through radiation, oxidative stress, DNA damage, or simply repeated division — they enter a state called cellular senescence. They stop dividing but refuse to die, instead secreting a toxic cocktail of inflammatory cytokines, chemokines, and tissue-remodeling enzymes known as the senescence-associated secretory phenotype (SASP). A few senescent cells in a young tissue are harmless. With age, their numbers grow, their SASP output poisons surrounding tissue, and they drive a surprising fraction of age-related disease — arthritis, atherosclerosis, frailty, fibrosis, cognitive decline, and type-2 diabetes. Mouse studies have shown that simply removing senescent cells extends healthspan and reduces multimorbidity.

The Mayo Clinic Fisetin Study

In 2018, a research group led by James Kirkland at the Mayo Clinic screened ten flavonoid compounds for senolytic activity and identified fisetin as the most potent. A single course of fisetin in aged mice reduced senescent-cell burden in multiple tissues, restored tissue homeostasis, and extended median and maximum lifespan. The magnitude — and the fact that it was achieved in already-old animals — captured significant scientific attention and triggered a wave of human trials.

Mechanism — How Fisetin Eliminates Senescent Cells

Senescent cells survive by over-expressing anti-apoptotic proteins — the “SCAPs” (senescent-cell anti-apoptotic pathways). Fisetin inhibits several of these (notably BCL-xL and PI3K/AKT signaling), tipping already-stressed senescent cells into programmed cell death while leaving healthy cells unharmed. This selectivity is what distinguishes senolytics from conventional cytotoxic drugs.

Beyond Senolytics: Antioxidant, Anti-Inflammatory, Neuroprotective

Current Human Trials

Human trials include Mayo Clinic’s Alleviation by Fisetin of Frailty, Inflammation, and Related Measures (AFFIRM) and trials for age-related osteoarthritis, chronic kidney disease, and diabetic kidney disease. Early results have shown reductions in circulating senescent-cell markers and inflammatory cytokines in older adults. Larger efficacy trials remain ongoing.

Dosing Approaches

Most human studies use a pulsed “hit and run” approach — high doses for 2–3 consecutive days, repeated every few weeks or months — rather than daily continuous dosing. This matches the biology: senescent cells take weeks to accumulate, so continuous suppression is unnecessary. Typical research doses are 20 mg/kg body weight per day for two consecutive days, usually taken with fat-containing meals for absorption. Bioavailability is modest; formulations with liposomal encapsulation, phytosomes (e.g., Phytosome fisetin), or co-administration with black pepper piperine aim to address this.

Food Sources

Dietary intake alone does not reach the doses used in trials, but regular strawberry consumption contributes to overall flavonoid status along with its many other nutritional benefits.

Safety and Limits of the Evidence

Fisetin has excellent safety in short-term dosing. Long-term safety in humans at senolytic doses has not been fully characterized. Because it has some antiplatelet activity, caution is reasonable around major surgery and with anticoagulant medications. The field is moving fast but still immature: claims that fisetin is a proven anti-aging therapy are premature, while claims that it is “just another antioxidant” now look dated. A cautious but engaged approach — following trial results, dosing intermittently if at all, and prioritizing the many other longevity levers — is the honest position.


Research Papers

Selected peer-reviewed literature. Links resolve to PubMed or DOI.

  1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
  2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.
  3. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.
  4. Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr. 2009;4(4):297-307.
  5. Currais A, Prior M, Dargusch R, et al. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell. 2014;13(2):379-390.
  6. Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151-162.
  7. Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol. J Nutr. 2000;130(9):2243-2250.
  8. Prior M, Chiruta C, Currais A, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014;5(7):503-513.
  9. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
  10. PubMed — fisetin senolytic clinical trial search.
  11. PubMed — fisetin neuroprotection search.
  12. ClinicalTrials.gov — active fisetin trials.

Back to Table of Contents


Connections

↑ Back to Table of Contents


Video Thumbnail

Fisetin for Anti-Aging, Longevity and Reversal of Age Related Disease? | How and Why I take Fisetin

Video Thumbnail

Fisetin Kills Zombie Cells, but there’s A BIG PROBLEM

Video Thumbnail

Science Failed FISETIN - Here's Why

Video Thumbnail

FISETIN: more effective "brother" of quercetin. Can in treat cancer? Other body effects.

Video Thumbnail

FISETIN is medicine against AGING and CANCER.

Video Thumbnail

Fisetin: The Shocking Truth About Zombie Cells

Video Thumbnail

Results After Switching To Fisetin Daily

Video Thumbnail

Fisetin - The Anti-Aging Compound Hiding in Strawberries

Video Thumbnail

FISETIN: How it AFFECTS Senescent Cells